Gain Therapeutics, Inc.
General ticker "GANX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $52.6M (TTM average)
Gain Therapeutics, Inc. follows the US Stock Market performance with the rate: 22.6%.
Estimated limits based on current volatility of 5.9%: low 3.10$, high 3.48$
Factors to consider:
- Total employees count: 31 (+24.0%) as of 2022
- Top business risk factors: Substantial doubt about continuing as a going concern, Market acceptance, Need for additional capital, ESG risks, Regulatory and compliance
- Current price 11.2% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.11$, 3.15$]
- 2025-12-31 to 2026-12-31 estimated range: [1.12$, 3.12$]
Financial Metrics affecting the GANX estimates:
- Positive: with PPE of -1.9 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -47.80 <= 0.33
- Positive: Interest expense per share per price, % of 0 <= 0.01
- Positive: Investing cash flow per share per price, % of 12.61 > -0.66
- Positive: 41.86 < Shareholder equity ratio, % of 60.54 <= 63.39
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -4.69 <= -0.75
Short-term GANX quotes
Long-term GANX plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.13MM | $0.06MM | $0.00MM |
| Operating Expenses | $17.91MM | $22.31MM | $20.35MM |
| Operating Income | $-17.78MM | $-22.25MM | $-20.35MM |
| Non-Operating Income | $0.28MM | $0.06MM | $0.48MM |
| R&D Expense | $8.46MM | $11.52MM | $10.79MM |
| Income(Loss) | $-17.50MM | $-22.19MM | $-19.87MM |
| Taxes | $0.09MM | $0.08MM | $0.54MM |
| Profit(Loss)* | $-17.59MM | $-22.27MM | $-20.41MM |
| Stockholders Equity | $18.88MM | $12.58MM | $7.34MM |
| Assets | $24.10MM | $18.61MM | $12.12MM |
| Operating Cash Flow | $-14.69MM | $-18.87MM | $-18.87MM |
| Capital expenditure | $0.12MM | $0.02MM | $0.02MM |
| Investing Cash Flow | $-14.77MM | $10.22MM | $4.98MM |
| Financing Cash Flow | $-0.08MM | $12.64MM | $13.01MM |
| Earnings Per Share** | $-1.48 | $-1.71 | $-0.89 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.